Max Neeman is part of the global study enrolling patients with Relapsing-Remitting Multiple Sclerosis. This multi-center study spans across thirty countries which includes India. The study aims to enroll a total of 120 patients in India.
For more details on the study, please visit:
http://www.clinicaltrial.gov/ct2/show/NCT00451451?term=109MS302&rank=1&show_locs=Y#locn
|